Emerald Advisers LLC Grows Position in Savara Inc. (NASDAQ:SVRA)

Emerald Advisers LLC lifted its stake in shares of Savara Inc. (NASDAQ:SVRA - Free Report) by 32.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,090,213 shares of the company's stock after acquiring an additional 757,533 shares during the quarter. Emerald Advisers LLC owned approximately 1.79% of Savara worth $8,560,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Cibc World Markets Corp purchased a new position in shares of Savara during the fourth quarter valued at approximately $33,000. XTX Topco Ltd purchased a new position in shares of Savara during the fourth quarter valued at approximately $34,000. Ameriprise Financial Inc. purchased a new position in shares of Savara during the fourth quarter valued at approximately $37,000. KLP Kapitalforvaltning AS purchased a new position in Savara in the fourth quarter worth $41,000. Finally, Hsbc Holdings PLC purchased a new position in Savara in the fourth quarter worth $48,000. 87.93% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on SVRA. Wells Fargo & Company lowered their target price on Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 28th. HC Wainwright lowered Savara from a "buy" rating to a "neutral" rating and lowered their target price for the company from $6.00 to $2.00 in a research note on Thursday, May 29th. Evercore ISI lowered their target price on Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a research note on Wednesday, May 28th. Finally, Guggenheim restated a "buy" rating and issued a $8.00 target price (down from $9.00) on shares of Savara in a research note on Wednesday, May 28th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.60.

Savara Trading Up 0.9%

Shares of SVRA traded up $0.02 during mid-day trading on Wednesday, hitting $2.31. 690,589 shares of the company's stock traded hands, compared to its average volume of 1,265,053. The company has a quick ratio of 14.91, a current ratio of 14.91 and a debt-to-equity ratio of 0.20. Savara Inc. has a 1 year low of $1.89 and a 1 year high of $4.88. The firm has a market capitalization of $399.26 million, a P/E ratio of -4.81 and a beta of 0.31. The business's 50-day moving average price is $2.46 and its 200-day moving average price is $2.71.

Savara (NASDAQ:SVRA - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12). As a group, sell-side analysts forecast that Savara Inc. will post -0.45 EPS for the current fiscal year.

Insider Activity at Savara

In other news, Director Richard J. Hawkins purchased 48,225 shares of the company's stock in a transaction dated Friday, June 20th. The shares were purchased at an average cost of $2.04 per share, for a total transaction of $98,379.00. Following the purchase, the director directly owned 115,466 shares in the company, valued at approximately $235,550.64. This represents a 71.72% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 5.33% of the company's stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.